Bone graft source disclosure is missing from many implant consultations
A survey of dental implant patients has exposed a serious gap in consent conversations: 63% said their clinician did not discuss different bone graft materials before treatment. For a procedure that often depends on biomaterials with variable origins, the omission is not a minor communication lapse. It can alter whether a patient agrees to treatment at all.
The issue sits at the point where surgical planning meets personal belief. A proposed graft may be synthetic, animal-derived, or sourced from donated human tissue, and those distinctions can be decisive for patients whose religion, ethics, or lifestyle rules limit what may be placed in their bodies. For Muslim patients, vegans, and others with specific objections, the source of the graft is not a detail buried in the operative note; it is part of the decision to proceed.
Consent in implant dentistry extends beyond the drill and the implant
Mariam Belattar, an associate dentist, framed the problem in direct clinical terms: a material may be biologically suitable yet still be unacceptable to the person receiving it. In implant dentistry, that matters because grafting is often planned in advance, not rushed in a crisis. There is usually time to explain the material, its origin, and alternatives where they are clinically appropriate.
Belattar’s position places biomaterial sourcing squarely inside informed consent. That approach is consistent with the ethics of elective care. When a patient agrees to surgery, they are not consenting only to a flap, a fixture, or a postoperative healing period. They are also consenting to the composition of what enters their body, including whether a graft contains bovine-derived material, human donor tissue, or a synthetic substitute.
The survey data suggest that dentists are not consistently covering that ground. One quarter of respondents said their dentist did not ask whether religious beliefs or personal preferences might shape their material choice. In practice, that leaves the burden on patients to know what to ask, when many will assume the clinic has already screened for it.
Patients changed their minds when the graft source was explained
The survey also points to a likely downstream effect on treatment acceptance. Four in 10 respondents said they would have requested a synthetic material if they had known in advance that the graft came from an animal or a deceased human. Another 23% said they would have rejected that material outright.
Those numbers matter because they suggest the consent gap is not abstract. It can change the clinical plan, the prosthetic pathway, and the patient’s willingness to continue. A patient who learns about the source only after treatment may feel misled even if the procedure itself was technically successful. In implant dentistry, trust is not a soft endpoint. It affects whether patients return for maintenance, accept future procedures, or raise complaints when they feel a boundary has been crossed.
For clinicians, the biological suitability of a graft cannot be separated from its social acceptability. The graft may support bone regeneration exactly as intended, but if the patient would have declined it on religious or ethical grounds, the clinical success is incomplete from the patient’s perspective. Consent that ignores material origin is vulnerable to that kind of mismatch.
Regulatory expectations are moving in the same direction
The concern is not isolated to patient preference. In February 2026, the General Dental Council acknowledged concerns about patients not being informed of animal-derived dental materials, including bovine bone graft products. That acknowledgement gives the issue a regulatory dimension as well as an ethical one.
If a patient’s objection is foreseeable and avoidable, consent around material choice may become a fitness-to-practise concern rather than a simple communication miss. Dental teams that assume graft source is too technical to discuss risk undercutting the very consent process that protects both patient autonomy and clinical accountability. In elective implant care, where treatment can often be planned and discussed in advance, there is little justification for keeping biomaterial origin off the agenda.
Belattar argued that patients should be told clearly what material is being proposed, what its biological origin is, and what realistic alternatives exist. That is a practical standard, not an idealised one. It recognizes that some patients will proceed only if a synthetic option is available, while others may decline any material with animal or human origin regardless of its regenerative profile.
Religious and ethical objections are not peripheral concerns
Seven in 10 survey respondents said they expected their dentist to tell them if a graft came from an animal or human. Half of Muslim patients said they would make a complaint if animal-derived material had been used without disclosure. Those figures show that expectations are already set high, and the consequences of missing them are immediate.
The ethical stakes are straightforward. A patient cannot exercise genuine choice if they do not know what they are choosing. For some patients, the issue is not simply whether a graft integrates with bone, but whether its source is permissible at all. A clinician who omits that information may preserve procedural efficiency while weakening the legitimacy of the consent process.
Synthetic materials will likely appeal to some patients precisely because they avoid those conflicts. But the decision cannot be driven by marketing logic alone. The research behind the survey was commissioned by Ethoss Regeneration, a British manufacturer of synthetic bone materials, and that commercial context should be kept in view. Even so, the consent obligation described by Belattar stands apart from any single product or sponsor. The duty is broader than one company’s portfolio.
A patient who discovers the source only after surgery may not feel reassured by a technically sound outcome.
What implant teams need to document before treatment begins
The clearest lesson from the survey is not about product superiority. It is about disclosure. Before an implant-related graft is placed, patients should be told whether the material is synthetic, animal-derived, or sourced from donated human tissue, and they should be given a chance to state objections before treatment proceeds.
That conversation should be routine, not reserved for patients who volunteer a religious or ethical concern on their own. A careful history can uncover whether these issues matter to the individual sitting in the chair. When they do, the discussion needs to be explicit and recorded. If a clinic has reasonable alternatives, those should be explained in plain language rather than buried in technical terminology.
The practical consequence is immediate: better disclosure reduces the risk of consent disputes and helps ensure that implant planning matches the values of the person undergoing care. Without that step, dentists may be relying on silent assumptions about acceptability that do not hold in real practice. The survey suggests those assumptions are already costing some patients the chance to make a truly informed decision.